Abstract: A fixing apparatus according to an embodiment includes: a first roller; a second roller that forms a nip between the second roller and the first roller and pressurizes a sheet passing through the nip against the first roller; a third roller that is disposed in parallel with the first and second rollers; a fixing belt that is stretched over the first and third rollers; a heater that uniformly heats the fixing belt in a direction of a width of the fixing belt; and a heat-uniformizing member that is a shaft-shaped heat-uniformizing member embedded in the third roller. An effective length in a longitudinal axial direction of the heat-uniformizing member is set to be the same or greater than a width of a predetermined maximum sheet so as to uniformly distribute heat of the fixing belt which is in contact with the third roller in the longitudinal axial direction.

Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.

Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.

Abstract: A fixing apparatus according to an embodiment includes: a first roller; a second roller that forms a nip between the second roller and the first roller and pressurizes a sheet passing through the nip against the first roller; a third roller that is disposed in parallel with the first and second rollers; a fixing belt that is stretched over the first and third rollers; a heater that uniformly heats the fixing belt in a direction of a width of the fixing belt; and a heat-uniformizing member that is a shaft-shaped heat-uniformizing member embedded in the third roller. An effective length in a longitudinal axial direction of the heat-uniformizing member is set to be the same or greater than a width of a predetermined maximum sheet so as to uniformly distribute heat of the fixing belt which is in contact with the third roller in the longitudinal axial direction.

Abstract: According to one embodiment, a fixing device includes a fixing roller having an elastic layer, a fixing belt wound around the fixing roller, a satellite roller to set up the fixing belt between the fixing roller and the satellite roller, a pressing roller to nip hold the fixing belt between the fixing roller and the pressing roller, a separator to separate a sheet at a position separate from the fixing belt, a pressure changing mechanism to change a nip pressure between the fixing roller and the pressing roller, and a driving device to rotate the fixing belt in a first direction when the nip pressure is a first nip pressure and to rotate the fixing belt in a second direction which is reverse to the first direction when the nip pressure is a second nip pressure which is lower than the first nip pressure.

Abstract: In a cooling mechanism for a fixing device according to an embodiment of the invention, a duct that flows outer air taken in by a fan is attached firmly to a slit formed between a bent coil part at an end part of a coil and a magnetic core in an induction heating device. The bent coil part is directly cooled without exerting influence of outer air on a heat roller, and temperature rise in the bent coil part is securely prevented.

Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

Abstract: It has now been discovered that inhibitors of soluble epoxide hydrolase (“sEH”) are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosantrienoic acid (“EET”) in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced numbers of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.

Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.

Abstract: In a cooing mechanism for a fixing device according to an embodiment of the invention, a duct that flows outer air taken in by a fan is attached firmly to a slit formed between a bent coil part at an end part of a coil and a magnetic core in an induction heating device. The bent coil part is directly cooled without exerting influence of outer air on a heat roller, and temperature rise in the bent coil part is securely prevented.

Abstract: The invention provides methods for alleviating eye disorders due to increased intraocular pressure (“IOP”) or inflammation by administering to the eye or eyes of an individual in need thereof a cis-epoxyeicosatrienoic acid, an inhibitor of soluble epoxide hydrolase (sEH), or both. The invention further provides for reducing IOP or inflammation by methods in which the sEH inhibitor or EETs, or both, are administered systemically. In some embodiments, the methods comprise administering to the individual a nucleic acid encoding an inhibitor of sEH.

Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

Abstract: It has now been discovered that inhibitors of soluble epoxide hydrolase (“sEH”) are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosantrienoic acid (“EET”) in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced numbers of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.

Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.

Abstract: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.